Literature DB >> 8119236

Graves' ophthalmopathy: current concepts regarding pathogenesis and management.

H B Burch1, L Wartofsky.   

Abstract

Referring to the hyperadrenergic theory on the pathogenesis of Graves' ophthalmopathy, a 1934 JAMA editorial (513) stated "the mechanism of exophthalmos is well understood though the knowledge would seem to be poorly disseminated." Several subsequent theories on pathogenesis, stated equally emphatically, have experienced a similar fate to that prompting this remark, but not before negatively impacting upon the management of patients suffering from this disorder. Thus, it is with an element of caution that we conclude that the sequence of events contributing to the pathogenesis of Graves' ophthalmopathy has become progressively more lucid, due to the assiduous efforts of many investigators in this field. Demonstration of an inextricable link between the eye and the thyroid in Graves' ophthalmopathy seems limited only by our ability to detect subtle involvement of one or the other of these two organs in exceptional cases, although not all authors share this viewpoint (514). The factors modulating the degree of expression of the thyroid component, such as concurrent lymphocytic thyroiditis or qualitative differences in TRAb seem more tangible than those affecting the clinical expression of eye involvement. Environmental factors such as smoking are associated, to a degree that matches or surpasses that known for genetic predisposition to this disorder. Local anatomy, including such factors as vulnerability to obstruction of venous drainage, must play a role as evidenced by asymmetric eye involvement and rapid relief of inflammatory changes after orbital decompression surgery. The transition from palliative to curative measures in Graves' ophthalmopathy will require further advances in our understanding of the putative shared thyroid-eye antigens, demonstration that these antigens are etiologically important and concomitant advances in antigen-specific immune therapy.

Entities:  

Mesh:

Year:  1993        PMID: 8119236     DOI: 10.1210/edrv-14-6-747

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  103 in total

1.  Radioiodine and thyroid eye disease.

Authors:  J P Walsh; C M Dayan; M J Potts
Journal:  BMJ       Date:  1999-07-10

Review 2.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

3.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 4.  Diagnosis and management of Graves' disease.

Authors:  Jody Ginsberg
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

5.  Unilateral proptosis: the role of medical history.

Authors:  N Kamminga; N M Jansonius; J W R Pott; T P Links
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

6.  Thyroid Eye Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

7.  Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2015-09-01       Impact factor: 2.447

8.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

9.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

Review 10.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.